Masahiro Onozawa
Overview
Explore the profile of Masahiro Onozawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
1401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makishima H, Mikasa T, Isogaya K, Miyamoto T, Yamauchi T, Yokota A, et al.
Int J Hematol
. 2025 Feb;
PMID: 40016445
This phase 1/2 study investigated the association between genetic characteristics and outcomes for NS-87/CPX-351 in Japanese patients with high-risk acute myeloid leukemia. Blood samples collected from 29 patients were analyzed...
2.
Miyashita N, Onozawa M, Kasahara K, Matsukawa T, Onodera Y, Suzuki K, et al.
Cancer Sci
. 2025 Feb;
PMID: 39905783
In this study, the mechanisms of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML) were investigated focusing additional sex combs-like 1 (ASXL1) gene mutations and their downstream effects....
3.
Yokoyama E, Hasegawa Y, Wakaki K, Suzuki T, Kajikawa S, Kanaya M, et al.
Int J Hematol
. 2025 Jan;
PMID: 39888516
Chronic graft-versus-host disease (cGVHD) is a major serious complication after allogeneic stem-cell transplantation (allo-HSCT), and often mimics autoimmune diseases. Central nervous system (CNS) symptoms are rare manifestations of cGVHD, and...
4.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
Blood
. 2025 Jan;
PMID: 39775763
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute...
5.
Matsukawa T, Onozawa M, Kondo T, Kanaya M, Hidaka D, Ota S, et al.
Ann Hematol
. 2024 Nov;
103(12):5333-5340.
PMID: 39614924
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types...
6.
Goto H, Onozawa M, Teshima T
Int J Hematol
. 2024 May;
120(1):6-14.
PMID: 38795249
Approximately 60-70% of patients with large B cell lymphoma (LBCL) achieve long-term remission or a cure after initial treatment. However, patients who relapse or are refractory to initial treatment have...
7.
Kosaka N, Uchiyama T, Onozawa M, Nagai J, Koya J, Ishizaka S, et al.
Intern Med
. 2024 Apr;
63(24):3359-3365.
PMID: 38631853
We herein present a fatal case of constrictive pericarditis (CP) due to acute myelomonocytic leukemia (AMML) in a patient who initially complained of an acute onset of chest pain two...
8.
Kimura H, Onozawa M, Matsukawa T, Goto H, Kondo T, Teshima T
Exp Hematol
. 2024 Mar;
134:104208.
PMID: 38548144
Germline mutations of THPO were reported as causes of hereditary thrombocythemia. Six previously reported distinct sites of the mutation were clustered at the 5`-untranslated region or the exon 3 splicing...
9.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, et al.
Int J Hematol
. 2024 Mar;
119(6):647-659.
PMID: 38532078
Objectives: NS-87/CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin. NS-87/CPX-351 exerts antileukemic action by maintaining a synergistic molar ratio of cytarabine to daunorubicin of 5:1 within the liposome...
10.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
J Clin Oncol
. 2024 Mar;
42(15):1766-1775.
PMID: 38471061
Purpose: Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of () AML. These patients are routinely treated with a FLT3 inhibitor...